Abstract
Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13. Efficacy and safety of dupilumab in 6–11-year-old children with uncontrolled, moderate-to-severe asthma were demonstrated in VOYAGE (NCT02948959). The EXCURSION open-label extension study (NCT03560466) assessed dupilumab long-term safety and efficacy in children who completed VOYAGE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
